isoprenaline   Click here for help

GtoPdb Ligand ID: 536

Synonyms: isoproterenol | Isuprel® | Medihaler-Iso®
Approved drug
isoprenaline is an approved drug
Compound class: Synthetic organic
Comment: Isoprenaline is a β-adrenoceptor agonist drug.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 4
Rotatable bonds 4
Topological polar surface area 72.72
Molecular weight 211.12
XLogP 1.16
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(NCC(c1ccc(c(c1)O)O)O)C
Isomeric SMILES CC(NCC(c1ccc(c(c1)O)O)O)C
InChI InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
InChI Key JWZZKOKVBUJMES-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor.
J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385]
3. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.
PLoS ONE, 5 (11): e15487. [PMID:21152092]
4. Baker JG. (2010)
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Br J Pharmacol, 160 (5): 1048-61. [PMID:20590599]
5. Baker JG, Hall IP, Hill SJ. (2002)
Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Br J Pharmacol, 137 (3): 400-8. [PMID:12237261]
6. Baker JG, Hall IP, Hill SJ. (2003)
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.
Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341]
7. Baker JG, Hall IP, Hill SJ. (2003)
Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses.
Mol Pharmacol, 64 (3): 679-88. [PMID:12920204]
8. Baker JG, Hall IP, Hill SJ. (2004)
Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production.
Mol Pharmacol, 65 (4): 986-98. [PMID:15044629]
9. Baker JG, Proudman RG, Hawley NC, Fischer PM, Hill SJ. (2008)
Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human beta1-adrenoceptor.
Mol Pharmacol, 74 (5): 1246-60. [PMID:18687809]
10. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.
PLoS One, 8 (11): e77582. [PMID:24250787]
11. Blin N, Nahmias C, Drumare MF, Strosberg AD. (1994)
Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor.
Br J Pharmacol, 112 (3): 911-9. [PMID:7921620]
12. De Pascali F, Ippolito M, Wolfe E, Komolov KE, Hopfinger N, Lemenze D, Kim N, Armen RS, An SS, Scott CP et al.. (2022)
β2 -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the β2 -adrenoceptor with possible implications for the treatment of asthma.
Br J Pharmacol, 179 (19): 4692-4708. [PMID:35732075]
13. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020)
The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors.
Pharmacol Res Perspect, 8 (5): e00643. [PMID:32813332]
14. Frielle T, Daniel KW, Caron MG, Lefkowitz RJ. (1988)
Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Proc Natl Acad Sci USA, 85 (24): 9494-8. [PMID:2849109]
15. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. (2004)
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Naunyn Schmiedebergs Arch Pharmacol, 369 (2): 151-9. [PMID:14730417]
16. Isogaya M, Sugimoto Y, Tanimura R, Tanaka R, Kikkawa H, Nagao T, Kurose H. (1999)
Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Mol Pharmacol, 56 (5): 875-85. [PMID:10531390]
17. Molenaar P, Sarsero D, Arch JR, Kelly J, Henson SM, Kaumann AJ. (1997)
Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
Br J Pharmacol, 120 (2): 165-76. [PMID:9117106]
18. Méjean A, Guillaume JL, Strosberg AD. (1995)
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
Eur J Pharmacol, 291 (3): 359-66. [PMID:8719421]
19. Popp BD, Hutchinson DS, Evans BA, Summers RJ. (2004)
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
Eur J Pharmacol, 484 (2-3): 323-31. [PMID:14744619]
20. Sato Y, Kurose H, Isogaya M, Nagao T. (1996)
Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
Eur J Pharmacol, 315 (3): 363-7. [PMID:8982677]
21. Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, Knowles RG. (2013)
In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
J Pharmacol Exp Ther, 344 (1): 218-30. [PMID:23131596]
22. Strosberg AD. (1997)
Structure and function of the beta 3-adrenergic receptor.
Annu Rev Pharmacol Toxicol, 37: 421-50. [PMID:9131260]
23. van Wieringen JP, Michel-Reher MB, Hatanaka T, Ueshima K, Michel MC. (2013)
The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3-adrenoceptors.
Eur J Pharmacol, 720 (1-3): 124-30. [PMID:24183974]
24. Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. (2023)
Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density.
PLoS One, 18 (9): e0290685. [PMID:37656760]